Table 3.
Compound | Cellsa IC50b [µg/mL]; Confident interval | |||||
---|---|---|---|---|---|---|
HL-60 | SF-295 | HCT-8 | MDA-MB-435 | PBMC | ||
12 | 2.3(1.3-3.9) | 6.0 (4.6-7.9) | 5.2(2.4-11.2) | 5.6(3.8-8.4) | >25 | |
13 | >25 | >25 | >25 | >25 | Nd | |
14 | >25 | >25 | >25 | >25 | Nd | |
16 | >25 | >25 | >25 | >25 | Nd | |
17 | >25 | >25 | >25 | >25 | Nd | |
18 | >25 | >25 | >25 | >25 | Nd | |
19 | >25 | >25 | >25 | >25 | Nd | |
20 | 20.3(17.6-23.4) | 11.3(8.6-14.9) | 13.5(9.1-20.1) | 21.5(18.7-24.8) | 21,8 (15,6-30,1) | |
21 | >25 | >25 | >25 | >25 | Nd | |
22 | >25 | >25 | >25 | >25 | Nd | |
23 | >25 | >25 | >25 | >25 | Nd | |
Doxorrubicin | 0.02(0.01-0.02) | 0.23(0.19-0.25) | 0.01(0.01-0.02) | 0.48(0.34-0.66) | 0,96 (0,51-1,71) |
a Cells were plated in 96-well plates incubated under a 5% CO2 atmosphere at 37 °C for 72 h in the presence of pure compounds (0.39-25 μg/mL). Each concentration was tested in triplicate and the analyses were performed in duplicate; b Data are presented as IC50 [μg/mL] values and 95% confidence interval (given in parentheses) obtained from at least three independent experiments. Compound 15 was not evaluated due to limited amount. Nd: not determined.